Clinical Trial Update: Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab and gemcitabine with either cetuximab or erlotinib in advanced pancreatic cancer has completed and posted results in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Avastin (bevacizumab)
• ERBITUX (cetuximab)
• Gemzar (gemcitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-11-20